Waters (WAT) Q2 Revenue Jumps 9%
(NYSE:WAT), the analytical instruments and laboratory technology leader, released its Q2 2025 earnings on August 4, 2025. The company's results topped Wall Street estimates, reporting revenue of $771 million compared to the $748.66 million expected, and non-GAAP earnings per share of $2.95 versus estimates of $2.94. The quarter was notable for robust growth in pharmaceutical and industrial end-markets, strong performance in recurring revenue streams, and improved free cash flow (non-GAAP). Management also increased its full-year 2025 revenue and non-GAAP earnings guidance, reflecting confidence in the ongoing strength of its replacement cycle for core products and steady demand from regulated, high-volume industries. Overall, the quarter demonstrated solid operational execution and resilience while certain segments, like TA Instruments and Academic Government, remained under pressure.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Waters designs, manufactures, and sells high-performance instruments used for chemical analysis, including high-performance liquid chromatography (HPLC), ultra-performance liquid chromatography (UPLC), and mass spectrometry (MS) systems. These technologies are vital for quality control, drug development, and regulatory testing in sectors like pharmaceuticals, environmental monitoring, and food safety. The company generates revenue through the sale of these instruments as well as through ongoing service contracts and consumables, such as chromatography columns.
Source Fool.com
Waters Corp. Stock
We see a rather positive sentiment for Waters Corp. with 10 Buy predictions and 2 Sell predictions.
With a target price of 379 € there is a positive potential of 48.05% for Waters Corp. compared to the current price of 256.0 €.
